DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vfend (Voriconazole) - Summary



VFEND® (voriconazole), a triazole antifungal agent is available as a lyophilized powder for solution for intravenous infusion.

VFEND is indicated for use in patients 12 years of age and older in the treatment of the following fungal infections:

Invasive Aspergillosis

In clinical trials, the majority of isolates recovered were Aspergillus fumigatus. There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [ see Clinical Studies, and Clinical Pharmacology ].

Candidemia in Non-neutropenic Patients and the Following Candida Infections: Disseminated Infections in Skin and Infections in Abdomen, Kidney, Bladder Wall, and Wounds

[ see Clinical Studies, and Clinical Pharmacology ]

Esophageal Candidiasis

[ see Clinical Studies, and Clinical Pharmacology ]

Serious Fungal Infections Caused by Scedosporium apiospermum (Asexual Form of Pseudallescheria boydii) and Fusarium spp. Including Fusarium solani, in Patients Intolerant of, or Refractory to, Other Therapy

[ see Clinical Studies, and Clinical Pharmacology ]

Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.

See all Vfend indications & dosage >>


Published Studies Related to Vfend (Voriconazole)

Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis. [2014]
MIC values from 221 patients with monocular fungal keratitis... CONCLUSIONS: Decreased susceptibility to natamycin was associated with increased

Effectiveness of voriconazole in the treatment of Aspergillus fumigatus-associated asthma (EVITA3 study). [2014]
to A fumigatus... CONCLUSION: We were unable to show a beneficial effect of 3 months of treatment

The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. [2013]
filamentous fungal keratitis... CONCLUSIONS: Natamycin treatment was associated with significantly better

Voriconazole versus natamycin as primary treatment in fungal corneal ulcers. [2011.07]
BACKGROUND: To evaluate the efficacy of topical 1% voriconazole versus 5% natamycin in treatment of fungal corneal ulcers. DESIGN: A prospective, randomized pilot study in a tertiary care hospital. PARTICIPANTS: Thirty patients of microbiologically proven fungal keratitis divided randomly in two groups of 15 patients each... CONCLUSION: Topical 1% voriconazole was found to be safe and effective drug in primary management of fungal keratitis, its efficacy matching conventional natamycin. There was no added advantage of using topical 1% voriconazole over topical natamycin as primary treatment in fungal keratitis. (c) 2011 The Authors. Clinical and Experimental Ophthalmology (c) 2011 Royal Australian and New Zealand College of Ophthalmologists.

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. [2011.01]
PURPOSE: To compare the efficacy and safety of voriconazole with itraconazole as prophylaxis in leukemia patients... CONCLUSIONS: Voriconazole is a good alternative for prophylaxis in patients with leukemia. Elevated baseline bilirubin levels were associated with a higher risk of side effects in patients receiving i.v. voriconazole or i.v. itraconazole. Monitoring of liver function and drug levels should be considered for some patients.

more studies >>

Clinical Trials Related to Vfend (Voriconazole)

Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) [Completed]

Voriconazole (Vfend) Special Investigation (Regulatory Post Marketing Commitment Plan) [Completed]

Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy [Suspended]
This is a trial to determine whether giving a patient a tailored dose of voriconazole is safe and effective.

To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days [Completed]

Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g [Completed]
The primary objective of the study is to assess the relationship (both crude and adjusted) between voriconazole utilization and the development of non-melanoma skin cancer among adult patients who received a lung or heart/lung transplant and were continuously enrolled in a large U. S. commercial health plan.

more trials >>

Reports of Suspected Vfend (Voriconazole) Side Effects

Death (97)Disease Progression (38)Photosensitivity Reaction (37)Pneumonia (23)Visual Impairment (23)Renal Failure (19)Malaise (17)Drug Interaction (16)NO Adverse Event (16)Hepatic Function Abnormal (15)more >>

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017